 Tiziana Life Sciences plc NASDAQ: TLSA has provided an update on further analysis of lymphocyte subsets from a Phase 1 study with nasally administered foralumab in healthy volunteers. Data showed statistically significant immunomodulatory effects on CD8 cytotoxic T-lymphocytes and other inflammatory biomarkers. 